10 recruiting, 6 unknown, 2 active not recruiting, 2 completed. 7 Not applicable, 7 Phase 2, 2 Phase 3, 1 Phase 1.
Follow Circulating Tumor DNA: new trials by email Literature Review of Circulating Tumor DNA trials Research Report on Circulating Tumor DNA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctDNA and TEP Levels in Colon Cancer Additional Peripheral Venous Blood Sampling for ctDNA and TEP Biomarker Analysis - Colon Cancer | Not applicable | Not yet recruiting | Institute of Oncology Ljubljana | 80 | 2026-11-01 | 2026-10-07 |
| Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry - Prostate Cancer, Prostatic Neoplasms | Recruiting | Lithuanian University of Health Sciences | 70 | 2026-08-04 | 2026-10-14 | |
| Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC Circulating Tumor DNA (ctDNA) Testing (ctDNA-based Next-Generation Sequencing (NGS)) - Biliary Tract Cancer | Recruiting | CHA University | 200 | 2025-09-01 | 2026-03-18 | |
| Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients Biospecimen Collection, cfDNA or ctDNA Measurement, Electronic Health Record Review - Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8 | Not applicable | Recruiting | City of Hope Medical Center | 150 | 2025-08-29 | 2026-08-12 |
| Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer Circulating tumor DNA - Breast Cancer, Lymph Node Metastasis | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 100 | 2025-08-22 | 2026-09-02 |
| NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment Active Surveillance, Control arm - Definitive bladder treatment - Muscle-Invasive Bladder Carcinoma | Phase 2 / Phase 3 | Recruiting | Peter Black | 688 | 2025-07-28 | 2025-07-30 |
| UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT DNA, RNA, ctDNA, metabolomics - Uterine Sarcoma, Vulvar Cancer | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 190 | 2024-09-15 | 2024-09-03 | |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 992 | 2024-02-02 | 2026-10-29 |
| Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA circulating tumor DNA - Hepatocellular Carcinoma Resectable | Recruiting | Zhujiang Hospital | 255 | 2023-11-20 | 2026-03-20 | |
| Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer circulating tumor DNA - Locally Advanced Rectal Carcinoma, Circulating Tumor DNA | Phase 2 | Recruiting | Peking Union Medical College Hospital | 470 | 2023-02-03 | 2024-12-24 |
| Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention ctDNA and adjuvant therapy, ctDNA - Metastatic Colorectal Cancer, No Evidence of Disease Status | Not applicable | Unknown | Fudan University | 110 | 2022-06-24 | 2022-12-02 |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) Local ablative therapy, Blood collection to assess for ctDNA - Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 37 | 2022-06-15 | 2026-02-02 |
| Versatile Ampification Single-Molecule Detection in Liquid Biopsy Blood sampling in addition to the blood normally required for their clinical management, Blood plasma and circulating tumor DNA (ctDNA) - Liquid Biopsy, Melanoma (Skin) | Recruiting | Regina Elena Cancer Institute | 20 | 2022-04-27 | 2024-11-27 | |
| A Screening Study Targeting Tumor-specific Antigens blood collection for research (next generation sequencing [NGS]), blood collection for research (HLA typing), blood collection for research (circulating tumor DNA [ctDNA]) - Metastatic Colorectal Cancer, Stage II/III Colon Cancer | Completed | Gritstone bio, Inc. | 22 | 2021-12-14 | 2022-10-18 | |
| Hypoxia-driven Prostate Cancer Genomics (HYPROGEN) Optional non-IMP pimonidazole, CT-guided Bone Biopsy, TRUS-guided Targeted Transperineal Prostate Biopsy - Prostate Cancer, Hypoxia | Unknown | The Christie NHS Foundation Trust | 60 | 2021-10-03 | 2023-01-27 | |
| Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy Transoral Surgery, External Beam Radiation Therapy, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 15 | 2021-05-19 | 2026-08-14 |
| The Value of ctDNA on Chemotherapy Efficacy for mCRC ct-DNA - Circulating Tumor DNA | Not applicable | Unknown | Fudan University | 300 | 2020-09-23 | 2021-07-19 |
| Clinical Utility of Circulating Tumor DNA in Gastro-Esophageal Cancer Circulating tumor DNA - Esophageal Cancer, Gastric Cancer | Unknown | Copenhagen University Hospital, Rigshospitalet | 1950 | 2020-02-03 | 2020-10-06 | |
| Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer Intensity Modulated Radiation Therapy, Carboplatin, MD Anderson Symptom Inventory (MDASI)-Plus module - Esophagus Cancer, Esophageal Cancer | Phase 1 | Active not recruiting | Washington University School of Medicine | 12 | 2019-11-07 | 2026-07-13 |
| Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG Encorafenib, Binimetinib, Research Bloods - High Grade Glioma, BRAF V600E | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 5 | 2019-07-29 | 2024-10-31 |
Showing 20 of 24. Sign in to see all of them.
Colorectal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Glioblastoma (2) · Neoplasm, Residual (2) · Prostatic Neoplasms (2) · Stomach Neoplasms (2) · Astrocytoma (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Genetic Diseases, Inborn (1) · Glioma (1) · Gliosarcoma (1) · Hypoxia (1)
Fudan University (2) · Affiliated Hospital of Qinghai University (1) · CHA University (1) · Centre Hospitalier Universitaire, Amiens (1) · City of Hope Medical Center (1) · Copenhagen University Hospital, Rigshospitalet (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Gritstone bio, Inc. (1) · Helsinki University Central Hospital (1) · Institute of Oncology Ljubljana (1) · Lithuanian University of Health Sciences (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Peking Union Medical College Hospital (1) · Peter Black (1)
United States (8) · China (5) · Canada (2) · Finland (2) · Italy (2) · Denmark (1) · France (1) · Lithuania (1) · Slovenia (1) · South Korea (1) · United Kingdom (1)
Daniel Gomez, MD (1) · Gregory Vlacich, M.D., Ph.D. (1) · Hong Jae Chon, MD. PhD (1) · Ilkka Ilonen, PhD (1) · Johanna Hynninen, MD, PhD (1) · Karisa C Schreck, MD (1) · Marwan G Fakih (1) · Matin Imanguli, MD, DDS (1) · Matthew D Galsky (1) · Mingxin Pan (1) · Peter Black, MD (1) · Sampsa Hautaniemi, DTech, Prof (1) · Stuart A Grossman, MD (1) · Yara Abdou, MD (1)
PMID 37207655, PMID 39894522, PMID 40885189, PMID 41435753, PMID 42567733
P30CA033572 (1), P30CA072720 (1), U10CA180821 (1), UM1CA137443 (1)